8月8日，两家AI制药龙头公司Recursion和Exscientia宣布已达成最终协议合并。Recursion是英伟达力挺的AI制药公司，致力于构建大型生物分子生成式AI模型，以实现药物发现的工业化；Exscientia则是更“传统意义”上的AI制药公司，利用高精度数据进行药物筛选、设计与开发。

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs ...

Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

7×24小时Recursion Pharmaceuticals（RXRX）股票快讯，包括最近Recursion Pharmaceuticals Inc（RXRX）股票市场行情资讯和影响股票涨跌的国际与经济时事。今日Recursion Pharmaceuticals股票最新消息与行情走势尽在掌握。 递归制药公司（Recursion Pharmaceuticals Inc.，股票代码：RXRX）股价在 ...

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...